SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES
31 mars 2020 14h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced it has entered into a research testing agreement with The University of Texas Medical...
Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program
25 mars 2020 10h00 HE
|
Sorrento Therapeutics, Inc.
STI-6991 is an I-CellTM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virusThe I-Cell vaccine is...
SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19
24 mars 2020 09h32 HE
|
Sorrento Therapeutics, Inc.
ACE-MABTM is a proprietary bi-specific fusion protein that binds to the spike protein of coronaviruses, including SARS-CoV-2 and SARS-CoV, which is expected to block SARS-CoV-2 from binding and...
SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)
20 mars 2020 07h00 HE
|
Sorrento Therapeutics, Inc.
COVIDTRAPTM is a proprietary ACE2-Fc protein that binds to the S1 domain of the spike protein of the SARS-CoV-2 virus;COVIDTRAP is designed to block the SARS-CoV-2 virus from binding and infecting...
Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference
27 févr. 2020 06h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will present at the 9th Annual LEERINK...
Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global Healthcare Conference
21 févr. 2020 09h15 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will present at LEERINK Partners 9th Annual Global Healthcare Conference...
Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal
10 janv. 2020 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento” or the “Company”), announced today that on January 9, 2020, it received a non-binding proposal from...
Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China
06 janv. 2020 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm (HK:2181) filed recently a New Drug Application for the Infliximab...
Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors
16 déc. 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that Robin L. Smith, MD, MBA has been appointed to its Board of Directors. Dr....
Sorrento Announces New Board Member
09 déc. 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that Mr. Edgar Lee has been appointed to its Board of Directors. Mr. Lee is...